| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ITRM | 6.500% Exchangeable Senior Subordinated Note due 2025 | Other | -$2.21M | $0 | Jan 13, 2025 | Ordinary Shares | 1.21M | By New Leaf Ventures III, L.P. | F1, F2, F3, F4, F5 | ||||
| transaction | ITRM | 6.500% Exchangeable Senior Subordinated Note due 2025 | Other | -$792K | $0 | Jan 13, 2025 | Ordinary Shares | 433K | By New Leaf Biopharma Opportunities II, L.P. | F1, F2, F3, F4, F6 |
| Id | Content |
|---|---|
| F1 | On January 21, 2020, Iterum Therapeutics Bermuda Limited (the "Issuer"), a wholly-owned subsidiary of Iterum Therapeutics plc (the "Company"), issued and sold, among other things, 6.500% exchangeable senior subordinated notes due 2025 (the "Exchangeable Notes") pursuant to a securities purchase agreement among the Issuer, the Company, the Company's wholly-owned subsidiaries and a group of accredited investors. The Exchangeable Notes were exchangeable into, at the Company's election, ordinary shares, nominal value $0.01 per share of the Company (the "Ordinary Shares"), cash or a combination of Ordinary Shares and cash, at an initial exchange rate of 1,000 Ordinary Shares per $1,000 principal amount of Exchangeable Notes (equivalent to an initial exchange price of approximately $1.00 per Ordinary Share), subject to anti-dilution adjustments as set forth in the indenture governing the Exchangeable Notes. |
| F2 | (Continued from Footnote 1) Subject to the terms of the indenture governing the Exchangeable Notes (the "Indenture"), on or after January 21, 2021 until January 13, 2025, the second scheduled trading day immediately preceding January 15, 2025, holders could exchange the Exchangeable Notes (the "Final Exchange Date"). The Exchangeable Notes mature on January 31, 2025, unless earlier exchanged, redeemed or repurchased in accordance with their terms. |
| F3 | In accordance with the terms of the Indenture, the Exchangeable Notes are no longer exchangeable after the Final Exchange Date. The Reporting Person did not sell or dispose of the Exchangeable Notes or the Ordinary Shares underlying the Exchangeable Notes. |
| F4 | Represents the amount of Ordinary Shares that were underlying the relevant Exchangeable Note based on the current exchange rate of 546.4481 Ordinary Shares per $1,000 of principal and interest on such Exchangeable Note. |
| F5 | The Exchangeable Note is held directly by New Leaf Ventures III, L.P. ("NLV-III"). New Leaf Venture Associates III, L.P. ("NLVA-III LP") is the general partner of NLV-III and New Leaf Venture Management III, L.L.C. ("NLVM-III LLC") is the general partner of NLVA-III LP, and each of NLVA-III LP and NLVM-III LLC may be deemed to have sole voting, investment and dispositive power with respect to the Exchangeable Note held by NLV-III. The Reporting Person, a member of the Company's Board of Directors, is a managing director of NLVM-III LLC and, in his capacity as a managing director, may be deemed to have shared voting, investment and dispositive power with respect to the Exchangeable Note held by NLV-III. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by NLV-III, except to the extent of his pecuniary interest therein, if any. |
| F6 | The Exchangeable Note is held directly by New Leaf Biopharma Opportunities II, L.P. ("NBPO-II"). New Leaf BPO Associates II, L.P. ("NBPO-IIA") is the general partner of NBPO-II and New Leaf BPO Management II, L.L.C. ("NBPO-IIM") is the general partner of NBPO-IIA, and each of NBPO-IIA and NBPO-IIM may be deemed to have sole voting, investment and dispositive power with respect to the Exchangeable Note held by NBPO-II. The Reporting Person, a member of the Company's Board of Directors, is a managing director of NBPO-IIM and, in his capacity as a managing director, may be deemed to have shared voting, investment and dispositive power with respect to the Exchangeable Note held by NBPO-II. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by NBPO-II, except to the extent of his pecuniary interest therein, if any. |